PipelineReview.com1h
U.S. FDA approves Celltrion’s AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA®
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
PipelineReview.com1h
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
MUNICH, Germany I January 30, 2025 I Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing ...
PipelineReview.com1d
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258
SAN MATEO, CA, USA I January 29, 2025 I Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...
PipelineReview.com2d
Kashiv Biosciences Announces Successful Phase 1 Results for Abatacept Biosimilar Candidate, KSHB002
PISCATAWAY, NJ, USA I January 28, 2025 I Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept ...
PipelineReview.com2d
miRecule and GBI Biomanufacturing Announce Strategic Partnership to Advance Development of Antibody RNA Conjugate (ARC) Therapies
PLANTATION, FL, and GAITHERSBURG, MD, USA I January 28, 2025 I miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a ...
PipelineReview.com2d
Helicore Biopharma Emerges from Stealth to Continue Advancing Portfolio of First-in-Class GIP Antagonists for Obesity and Related Conditions
SOUTH SAN FRANCISCO, CA, USA I8, 2025 I Helicore Biopharma Inc., a biopharmaceutical company focused on the discovery and development of ...
PipelineReview.com2d
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases
SOUTH SAN FRANCISCO, CA, USA I8, 2025 I Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the ...
PipelineReview.com3d
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
Trial anticipated for H2 2025 to evaluate most advanced next generation intranasal pertussis vaccine for whooping cough ...
PipelineReview.com3d
Triumvira Immunologics Presents Updated Clinical Data at the 2025 ASCO Gastrointestinal Cancers Symposium
AUSTIN, TX, USA and HAMILTON, Canada and SAN DIEGO, CA, USA I7, 2025 I Triumvira Immunologics, a clinical-stage company ...
PipelineReview.com3d
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
SAN FRANCISCO, CA, USA I7, 2025 I GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing ...
PipelineReview.com3d
Herantis Pharma: encouraging pharmacokinetic data and first subject with Parkinson’s disease dosed in the Phase 1b trial
I Herantis Pharma Plc ("Herantis"), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce an ...
PipelineReview.com3d
Akeso’s Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA
HONG KONG, China I January 26, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal ...